Why healthcare startups are struggling

With healthcare being the largest employer in the U.S. and projected to reach 20% of national GDP in the coming years, the sector is ripe with startups looking to make a stake. However, digital health startups are struggling, even with an influx of investment cash, as a result of the current market, according to Justin Barad, MD, co-founder of surgical training platform Osso VR.

Barad penned an article for TechCrunch on the market struggles healthcare startups currently face.

Part of the problem may be that tech companies are dipping their toes into healthcare using the tradition tech model: producing a product then finding uses for it. The same formula doesn’t work out in the more complex world of healthcare. Instead, the healthcare sector is more rewarding of needs-based innovations, according to Barad.

Despite this approach, the current ecosystem has “stunted” innovation, Barad argued, who laid out two “crushing challenges” to healthcare startups:

Institutional policies and hierarchical systems that maximize ownership and returns over innovation

Early-stage tech companies are misunderstood by the healthcare industry

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.